about
Cohort of Patients Infected by an ArbovirusBiomarkers in Urothelial Cancer Patients Treated With PembrolizumabStudy of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver CancerStudy of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Colorectal CancerStudy of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic CancerNeoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab and Urelumab Trial for Surgically Resectable Pancreatic CancerImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck CarcinomaPembrolizumab and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate CancerSequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLCPembrolizumab + Poly-ICLC in MRP Colon CancerOlaparib and Radium Ra 223 Dichloride in Treating Men With Metastatic Castration-Resistant Prostate Cancer That Has Spread to the BonePredictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell CarcinomaA Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid MalignanciesDurvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract CancerPembrolizumab + Idelalisib for Lung Cancer StudyDurvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation ApproachCombination Study of SV-BR-1-GM in Combination With PembrolizumabTailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell CarcinomaPersonalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)Nivolumab Plus Ipilimumab in Thyroid CancerRadiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCCAdjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and NeckAtezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain MetastasisAutologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Osteosarcoma, or Pancreatic Ductal AdenocarcinomaUnresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic CancerTrial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal MelanomaM7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung CancersRadio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the BladderDurvalumab for MSI-H or POLE Mutated Metastatic Colorectal CancerSBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLCA Study of a Personalized Neoantigen Cancer VaccinePaclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBCMolecular and Genomic Profiling of Head and Neck TumorsRapid Autopsy and Procurement of Cancer TissueGenetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant GliomaNivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal CancerPembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube CancerImmunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors.Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)
P8005
Q26780921-8063DEF5-52D8-4F63-80D7-0006D30147EEQ58407621-98CB0C98-E20D-44F9-BD0A-A8B7ADCAA55BQ58407658-541C1988-6B56-4F45-B3D5-82E1A90BF538Q58407661-EA28EEB6-A90A-414D-BE3F-D7C6A9D369ADQ58407666-23A3C148-03F9-4E61-A3E0-76E339139475Q58407666-C496BCC3-32B6-4C3A-A111-3F1CA2E886CAQ58407679-1A88755C-AFA8-47CD-8423-B076F2819C54Q58407687-4E50600B-D4DD-413B-B359-90698542D0CFQ58407704-94AF9847-5FB3-41AD-8612-6B8598F28F00Q58407710-CCC0EC38-33C8-41F0-AD63-DCAE61ECE08BQ58407728-C243D4E7-E60E-4CBA-BCEB-F75E5E88C67EQ58407741-7BB315D0-0280-483B-ACFD-4D4477D0E07DQ58407751-6C5C66E1-DC57-4E50-8664-E61CBD1CB7F1Q58407755-343420D7-8700-4CB0-A0E6-CF1BA315C6DEQ58407756-90337EDB-68A5-4DC3-821A-4BAFD5E66986Q58407778-C18832D9-23F3-4DF8-A328-3AA8BF419C60Q58407789-8DA5A875-FD7C-4702-8059-244BCFA4B22CQ58407801-1AD69506-4597-4462-89E1-A863ED73647AQ58407804-DA48D026-3A46-43E5-873F-F1906B347498Q58407810-3850FFEC-2F51-4376-87B6-3837E2FD0B8DQ58407823-D7B90C1A-099B-4E0B-98EC-A31B2943FA66Q58407832-224F0F23-313C-43F6-8726-A5DB7A45FBF7Q58407840-89F3308E-63D5-4A18-AE30-A40E6A32854FQ58407843-4831E287-48EB-487D-83CB-CC630F459A92Q58407852-AF099A25-9E00-4BE9-AABD-8BF73397336EQ58407854-DF069E7F-C099-442C-AAE7-C0A0A0776CEAQ58407866-D172FAFB-73C7-4735-BA1A-CD42F32E63D0Q58407869-89A45BD0-0E1E-4F87-9AE8-24FDEB50DB7FQ58407871-F6BDE32D-6B28-4016-A99E-FB85CCC253EDQ58407873-2A50FFF6-0161-4557-A4A6-C3E4ECE51A59Q58407876-4A269C71-64BC-4495-BA03-994046F1403CQ58407879-A4175A1A-32F9-47EC-9A9F-E1DF7A5A8186Q58407881-F2661E59-EAD4-4450-A958-2B12D708E1F6Q58407885-EAF7B566-B4FE-4E1B-BD96-92A7CE76AFC4Q58844341-44C11842-0961-4CD0-BD18-CB296F1E6003Q58844919-749CE305-1FCA-4579-8536-0D4548A0BC8DQ58845050-2B0C429D-FA0B-445E-9F07-BF5181031310Q58845050-D495B5B9-3EE4-45B5-A5DA-4EF0FAB140EFQ58845122-79BDCF1E-6121-48A3-A485-86F927B59C0BQ58845373-3607AC6F-5D1C-409B-9834-358191EEE05F
P8005
description
recruitment status in clinical trials
@en
name
reclutant
@ca
recruiting
@en
type
label
reclutant
@ca
recruiting
@en
prefLabel
reclutant
@ca
recruiting
@en